anti-Activin A Receptor Type II-Like 1 (ACVRL1) Antibodies

ACVRL1 encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. Additionally we are shipping ACVRL1 Proteins (26) and ACVRL1 Kits (22) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
ACVRL1 94 P37023
ACVRL1 25237 P80203
ACVRL1 11482 Q61288
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-ACVRL1 Antibodies at antibodies-online.com

Showing 10 out of 158 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Delivery Price Details
Dog Rabbit Un-conjugated WB WB Suggested Anti-ACVRL1 Antibody Titration:  0.2-1 ug/ml  Positive Control:  Jurkat cell lysate 100 μL 2 to 3 Days
$289.00
Details
Human Rabbit Un-conjugated IF (p), IHC (p), WB Formalin-fixed and paraffin embedded mouse cancer tissue labeled with Anti ACVRL1/ALK1 Polyclonal Antibody, Unconjugated (ABIN761261) at 1:300 followed by conjugation to the secondary antibody and DAB staining Formalin-fixed and paraffin embedded human colon carcinoma tissue labeled with Anti ACVRL1/ALK1 Polyclonal Antibody, Unconjugated (ABIN761261) at 1:200 followed by conjugation to the secondary antibody and DAB staining 100 μL 3 to 7 Days
$317.90
Details
Human Goat Un-conjugated ELISA, WB   100 μg 6 to 7 Days
$429.84
Details
Cow Rabbit Un-conjugated IC, IF, IHC, WB Immunofluorescent analysis of ALK1 staining in MCF7 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue). Immunohistochemical analysis of ALK1 staining in human brain formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. 200 μL 13 to 14 Days
$487.50
Details
Human Rabbit Un-conjugated EIA, IHC (p), WB 0.4 mL 6 to 8 Days
$484.00
Details
Human Rabbit Un-conjugated WB WB Image Sample (30 ug of whole cell lysate) A: U87-MG 7.5% SDS PAGE antibody diluted at 1:1000 100 μL 3 to 4 Days
$466.18
Details
Human Rabbit Un-conjugated WB WB Image Sample (30 ug of whole cell lysate) A:NIH-3T3 7.5% SDS PAGE antibody diluted at 1:1000 WB Image Sample(30 μg of whole cell lysate) A:Hep G2, 7.5% SDS PAGE antibody diluted at 1:1000 100 μL 3 to 4 Days
$466.18
Details
Human Rabbit Un-conjugated ELISA, IF, IHC, IHC (p), WB Anti-ACVRL1 / ALK-1 antibody IHC staining of human brain cerebellum. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody  ABIN1099926 concentration 5 ug/ml. 50 μL 11 to 14 Days
$484.00
Details
Bat Rabbit Un-conjugated WB 100 μL 11 to 14 Days
$551.83
Details
Human Rabbit Un-conjugated EIA, IF, IHC (p), WB 0.4 mL 6 to 8 Days
$484.00
Details

Top referenced anti-ACVRL1 Antibodies

  1. Human Polyclonal ACVRL1 Primary Antibody for IF, IHC (p) - ABIN544433 : Yu, Pisitkun, Wang, Shen, Knepper: LC-MS/MS analysis of apical and basolateral plasma membranes of rat renal collecting duct cells. in Molecular & cellular proteomics : MCP 2006 (PubMed)

  2. Human Polyclonal ACVRL1 Primary Antibody for IHC (p), ELISA - ABIN544434 : Johnson, Berg, Baldwin, Gallione, Marondel, Yoon, Stenzel, Speer, Pericak-Vance, Diamond, Guttmacher, Jackson, Attisano, Kucherlapati, Porteous, Marchuk: Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. in Nature genetics 1996 (PubMed)
    Show all 3 Pubmed References

  3. Human Polyclonal ACVRL1 Primary Antibody for IHC, IHC (p) - ABIN4279393 : Cunha, Pardali, Thorikay, Anderberg, Hawinkels, Goumans, Seehra, Heldin, ten Dijke, Pietras: Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. in The Journal of experimental medicine 2010 (PubMed)

More Antibodies against ACVRL1 Interaction Partners

Cow (Bovine) Activin A Receptor Type II-Like 1 (ACVRL1) interaction partners

  1. Results show that ALK5 and ALK1 play antagonistic roles in TGF-beta-induced podosome formation in aortic endothelial cells.

  2. ALK1 and ALK5 are both essential for correct regulation of VEGF, and that disruption of either pathway leads to disease.

Zebrafish Activin A Receptor Type II-Like 1 (ACVRL1) interaction partners

  1. alk1 loss has no effect on arterial endothelial cell proliferation but alters arterial endothelial cell migration within lumenized vessels.

  2. Control of Notch targets in arterial endothelium is context-dependent, with gene-specific and region-specific requirements for Notch and Alk1

  3. Blood flow is required not only for alk1 expression but also for Alk1 activity.

  4. Study demonstrate that alk1 expression requires blood flow, and despite normal levels of shear stress, some flow-responsive genes are dysregulated in alk1 mutant arterial endothelial cells.

  5. vbg encodes activin receptor-like kinase 1 (acvrl1), a TGFbeta type I receptor that is expressed predominantly in the endothelium of the vessels that become dilated in vbg mutants.

Human Activin A Receptor Type II-Like 1 (ACVRL1) interaction partners

  1. Despite the difficulty of interpreting deep intronic variants, our study highlights the importance of non-coding regions in the disease mechanism of HHT, particularly the CT-rich hotspot region of ACVRL1intron 9. The addition of this region to HHT molecular diagnostic testing algorithms will improve clinical sensitivity.

  2. Recurrent epistaxis is the main manifestation of hereditary hemorrhagic telangiectasia in this family. The mutation of ACVRL1 gene is the pathogenic gene of this family.

  3. The SNPs of the rs6435156 and rs1048829 locus in the BMPR2 gene, the rs121909287 loci in the ACVRL1 gene, and the rs397514716 locus in the SMAD9 gene were associated with a risk of essential hypertension (EH) in Han Chinese.

  4. Loss of ALK1 function in endothelial cells results in increased activity of the PI3K pathway and vascular hyperplasia.

  5. ACVRL1 expression could serve as a prognostic biomarker in metastatic colorectal cancer patients receiving chemotherapy and bevacizumab.

  6. Heterozygous SNP, rs372023206, was found in all tested patients with idiopathic pulmonary hypertension (heterozygosity).

  7. ENG, ACVRL1, and SMAD4 mutations result in different phenotypes in hereditary hemorrhagic telangiectasia

  8. ENG mutation carriers were more likely than ACVRL1 mutation carriers to have pAVMs (P < 0.001) or multiple lesions (P = 0.03), and to undergo procedural intervention (P = 0.02). The HHT severity score was significantly higher in ENG than in ACVRL1 (P = 0.02).

  9. These studies identified pathways mediating LDLR-independent uptake of LDL may provide unique opportunities to block the initiation of LDL accumulation in the vessel wall or augment hepatic LDLR-dependent clearance of LDL.

  10. We have identified a novel role for ALK1 in cardiac remodeling

  11. The present study showed that deletion-duplication mutations in the BMPR2 or ACVRL1 genes may not be associated with non-regression of Pulmonary arterial hypertension.

  12. Study identified 2 non-synonymous missense mutations: c.C652T, p.R218W in ACVRL1, c.C717G, p.D239E in SGCD in Chinese population with total anomalous pulmonary venous return.

  13. Mutations in ACVRL1 gene encoding for transforming growth factor (TGF)-[beta] superfamily have been identified in Pulmonary Arterial Hypertension.

  14. Treatment-related telangiectasia was noted in 7% of patients, suggesting in vivo inhibition of the ALK-1 pathway.

  15. Data indicate that simultaneous targeting of molecules that control distinct phases of angiogenesis, such as ALK1 and VEGFR, is a valid strategy for treatment of metastatic renal cell carcinoma (mRCC).

  16. Study showed that rs706819, rs2293094, and rs11169953 polymorphisms in the ACVRL1 gene are associated with higher susceptibility to brain arteriovenous malformations.

  17. c.1027C > T(p.Gln343) mutation within the ACVRL1 gene in family with hereditary hemorrhagic telangiectasia

  18. Bone morphogenetic protein (BMP)9 and BMP10 are high affinity ligands for activin receptor-like kinase 1 (ALK1).

  19. Activin receptor-like kinase (ALK)1 is a transforming growth factor beta (TGF-beta) type I receptor predominantly expressed in actively proliferating endothelial cells (ECs).

  20. Two novel missense mutations and two recurrent mutations in the ACVRL1 gene are associated with pulmonary arterial hypertension in in Chinese families.

Mouse (Murine) Activin A Receptor Type II-Like 1 (ACVRL1) interaction partners

  1. Loss of ALK1 function in endothelial cells results in increased activity of the PI3K pathway and vascular hyperplasia.

  2. our data show that in a tumor environment BMP9 and BMP10 play different roles and thus blocking their shared receptor ALK1 is maybe not appropriate. Indeed, BMP9, but not BMP10, acts as a quiescence factor on tumor growth, lung metastasis and vessel normalization.

  3. These studies identified pathways mediating LDLR-independent uptake of LDL may provide unique opportunities to block the initiation of LDL accumulation in the vessel wall or augment hepatic LDLR-dependent clearance of LDL.

  4. We have identified a novel role for ALK1 in cardiac remodeling

  5. Data show that concomitant activin receptor-like kinase 1 (Acvrl1) and endoglin (Eng) deficiency synergistically decreases pancreatic neuroendocrine tumor volume.

  6. Global deletion of AlK-1 is associated with the development of high output heart failure without maladaptive remodeling.

  7. These data indicate that both Itgb8 and Alk1 are important in maintaining normal cerebral angiogenesis in response to VEGF. Itgb8 deficiency enhances the formation of dysplastic vessels and hemorrhage in Alk1 (+/-) mice.

  8. these studies characterize an accessory TGF-beta-stimulated BMP R-Smad signaling mechanism in interstitial cells of the developing lung.

  9. this study demonstrates that ACVRL1 signaling plays a pivotal role whereby it suppresses plasmacytoid dendritic cell development while enhancing that of CD8alpha(+) dendritic cells, thus contributing to DC diversity development.

  10. CD109 differentially regulates TGF-beta-induced ALK1-Smad1/5 versus ALK5-Smad2/3 pathways, leading to decreased extracellular matrix production in the skin; epidermal CD109 expression regulates dermal function through a paracrine mechanism

  11. he results of the present study demonstrated that BMP9 promoted the osteoclast differentiation of osteoclast precursors via binding to the ALK1 receptor on the cell surface, and inhibiting the ERK1/2 signaling pathways in the cell

  12. Conclude that the ALK-1 receptor is involved in the control of arterial pressure. High AP of Alk1(+/-) mice is explained mainly by the sympathetic overactivation, which is probably related to the decreased number of cholinergic neurons.

  13. Report interaction between ALK1 signaling and connexin40 in the development of arteriovenous malformations.

  14. In vascular sprouting, neuropilin-1 suppresses the stalk-cell phenotype by limiting Smad2/3 activation through Alk1 and Alk5. Notch downregulates Nrp1, thus relieving the inhibition of Alk1 and Alk5, thereby driving stalk-cell behaviour.

  15. BMP9/ALK1 augmented vasculogenesis and angiogenesis, and thereby enhanced neovascularization. Thus, we suggest that BMP9/ALK1 may improve the efficacy of EPC-based therapies for treating ischemic diseases.

  16. BMP-9 induces vascular smooth muscle cell osteogenic differentiation and calcification via ALK1, Smad and ALP dependent mechanisms.

  17. during development, endothelial Acvrl1 plays an essential role to regulate endothelial cell proliferation and arterial identity during angiogenesis, whilst in adult life endothelial Acvrl1 is required to maintain vascular integrity.

  18. Results show that ALK5 and ALK1 play antagonistic roles in TGF-beta-induced podosome formation in aortic endothelial cells.

  19. ALK1 modulates obstruction-induced renal fibrosis by increased extracellular matrix synthesis in myofibroblasts, but without differences in myofibroblast number.

  20. the mechanisms responsible for the angiogenic imbalance and the response to anti-VEGF therapy differ between Eng and Alk1 heterozygous mice and raise the need for systemic monitoring of anti-angiogenic therapy effects in HHT patients.

ACVRL1 Antigen Profile

Protein Summary

This gene encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. The encoded protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hemorrhagic telangiectasia type 2, also known as Rendu-Osler-Weber syndrome 2.

Gene names and symbols associated with ACVRL1

  • activin A receptor like type 1 (ACVRL1) antibody
  • activin A receptor type II-like 1 (ACVRL1) antibody
  • activin A receptor like type 1 (acvrl1) antibody
  • activin A receptor like type 1 (Acvrl1) antibody
  • activin A receptor, type II-like 1 (Acvrl1) antibody
  • ACVRL1 antibody
  • Acvrlk1 antibody
  • AI115505 antibody
  • AI427544 antibody
  • ALK-1 antibody
  • Alk1 antibody
  • HHT antibody
  • HHT2 antibody
  • hm:zehn1109 antibody
  • ORW2 antibody
  • R-3 antibody
  • R3 antibody
  • SETHKIR antibody
  • SKR3 antibody
  • TSR-I antibody
  • vgb antibody
  • zehn1109 antibody

Protein level used designations for ACVRL1

activin A receptor type II-like 1 , serine/threonine-protein kinase receptor R3 , serine/threonine-protein kinase receptor R3-like , activin receptor-like kinase 1 , vbg , violet beauregarde , TGF-B superfamily receptor type I , activin A receptor, type II-like kinase 1 , Activin receptor like kinase 1 , SKR3 , TSR-I , ALK-1 , activin receptor-like kinase-1

GENE ID SPECIES
451910 Pan troglodytes
534536 Bos taurus
696471 Macaca mulatta
100061313 Equus caballus
100135773 Felis catus
100482358 Ailuropoda melanoleuca
266753 Danio rerio
94 Homo sapiens
25237 Rattus norvegicus
477603 Canis lupus familiaris
100153279 Sus scrofa
100172614 Pongo abelii
11482 Mus musculus
Selected quality suppliers for anti-ACVRL1 (ACVRL1) Antibodies
Did you look for something else?